drugset / Trial / NCT04106115
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
NaSingle-groupOpen-labelTreatment
Summary
DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer (NMIBC).
Timeline
- Start
- 2022-03-25
- Primary completion
- 2027-03-30
- Completion
- 2032-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | S-488210 | Vaccine | 1 ml | Subcutaneous |
| Subject | S-488211 | Vaccine | 1 ml | Subcutaneous |